Universität zu Köln

Kraemer, Max ORCID: 0009-0006-9275-6121, Zander, Thomas ORCID: 0000-0002-4266-6818, Alakus, Hakan ORCID: 0000-0002-3889-3276, Buettner, Reinhard ORCID: 0000-0001-8806-4786, Lyu, Su Ir ORCID: 0009-0002-4125-6048, Simon, Adrian Georg ORCID: 0000-0002-2709-863X, Schroeder, Wolfgang ORCID: 0000-0002-8700-069X, Bruns, Christiane J. ORCID: 0000-0001-6590-8181 and Quaas, Alexander ORCID: 0000-0002-3537-6011 (2024). Fetal gut cell-like differentiation in esophageal adenocarcinoma defines a rare tumor subtype with therapeutically relevant claudin-6 positivity and SWI/SNF gene alteration. Scientific Reports, 14 (1). pp. 1-7. Springer Nature. ISSN 2045-2322

PDF s41598-024-64116-2.pdf Bereitstellung unter der CC-Lizenz: Creative Commons Attribution. Download (1MB)

Abstract

[Artikel-Nr.: 114] Esophageal adenocarcinoma (EAC) is one of the deadliest tumor entities worldwide, with a 5-year survival rate of less than 25%. Unlike other tumor entities, personalized therapy options are rare, partly due to the lack of knowledge about specific subgroups. In this publication, we demonstrate a subgroup of patients with EAC in a large screening cohort of 826 patients, characterized by specific morphological and immunohistochemical features. This subgroup represents approximately 0.7% (6/826) of the total cohort. Morphological features of this subgroup show a striking clear cytoplasm of the tumour cells and the parallel existence of rare growth patterns like yolk sac-like differentiation and enteroblastic differentiation. Immunohistochemistry reveals expression of the fetal gut cell-like proteins Sal-like protein 4 (SALL4), claudin-6, and glypican 3. Interestingly, we find a correlation with alterations of SWI/SNF-complex associated genes, which are supposed to serve as tumor suppressor genes in various tumour entities. Our results suggest a possible implication of rare tumour subtypes in the WHO classification for EACs according to the classification for gastric cancer. Furthermore, claudin-6 positive tumors have shown promising efficacy of CAR T cell therapy in the recently published BNT-211-01 trial (NCT04503278). This represents a personalized therapeutic option for this tumor subtype.

Item Type:	Article
Creators:	Creators Email ORCID ORCID Put Code Kraemer, Max UNSPECIFIED https://orcid.org/0009-0006-9275-6121 UNSPECIFIED Zander, Thomas UNSPECIFIED https://orcid.org/0000-0002-4266-6818 UNSPECIFIED Alakus, Hakan UNSPECIFIED https://orcid.org/0000-0002-3889-3276 UNSPECIFIED Buettner, Reinhard UNSPECIFIED https://orcid.org/0000-0001-8806-4786 UNSPECIFIED Lyu, Su Ir UNSPECIFIED https://orcid.org/0009-0002-4125-6048 UNSPECIFIED Simon, Adrian Georg UNSPECIFIED https://orcid.org/0000-0002-2709-863X UNSPECIFIED Schroeder, Wolfgang UNSPECIFIED https://orcid.org/0000-0002-8700-069X UNSPECIFIED Bruns, Christiane J. UNSPECIFIED https://orcid.org/0000-0001-6590-8181 UNSPECIFIED Quaas, Alexander UNSPECIFIED https://orcid.org/0000-0002-3537-6011 UNSPECIFIED
URN:	urn:nbn:de:hbz:38-815668
Identification Number:	10.1038/s41598-024-64116-2
Journal or Publication Title:	Scientific Reports
Volume:	14
Number:	1
Page Range:	pp. 1-7
Number of Pages:	7
Date:	12 June 2024
Publisher:	Springer Nature
ISSN:	2045-2322
Language:	English
Faculty:	Faculty of Medicine
Divisions:	Faculty of Medicine > Chirurgie > Klinik und Poliklinik für Allgemein-, Viszeral-, Thorax- und Transplantationschirurgie Faculty of Medicine > Innere Medizin > Klinik I für Innere Medizin - Hämatologie und Onkologie Faculty of Medicine > Pathologie und Neuropathologie > Institut für Pathologie
Subjects:	Medical sciences Medicine
Uncontrolled Keywords:	Keywords Language Fetal-gut ; SALL4, Claudin-6 ; Glypican 3 ; SMARCA2-loss ; Esophageal adenocarcinoma ; Clear cell adenocarcinoma English
['eprint_fieldname_oa_funders' not defined]:	Publikationsfonds UzK
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/81566